1 drug(s) with this reaction
259 total reports
Injection Site Erythema has been reported as an adverse reaction across 1 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 259 adverse event reports mention injection site erythema in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with injection site erythema, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have injection site erythema listed in their FDA adverse event reports, sorted by report count:
In addition to injection site erythema, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
1 drug(s) manufactured by Amgen Inc have injection site erythema listed in their FDA adverse event reports: ROMOSOZUMAB-AQQG.
There are a combined 259 reports of injection site erythema across 1 Amgen Inc drug(s) in the FDA adverse event database.